News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No articles were published in the past hour.
  • No market-moving headlines emerged during the hour.
  • No new economic data releases occurred in the past hour.
  • No notable political developments were reported in the last hour.
  • No major global events were reported over the past hour.

Latest Articles

WeRide to Report Second Quarter and First Half 2026 Financial Results on Wednesday, August 12, 2026

WeRide to Report Second Quarter and First Half 2026 Financial Results on Wednesday, August 12, 2026

WeRide Inc., a global leader in autonomous driving technology and the first publicly traded Robotaxi company, announced it will release its unaudited second quarter and first half 2026 financial results on August 12, 2026, before the U.S. market opens. The company will hold a management earnings call the same day with English and Chinese simultaneo…

Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology

Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology

Trinity Biotech has announced a strategic collaboration and equity investment in Latch Medical to integrate its AI-native CGM+ biosensor platform with Latch's Pharma Latch microneedle drug delivery technology. The partnership aims to develop next-generation metabolic health solutions for diabetes, obesity, and related conditions by enabling real-ti…

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

BridgeBio Pharma announced FDA acceptance of its New Drug Application for encaleret, a potential disease-modifying oral therapy for autosomal dominant hypocalcemia type 1 (ADH1). The FDA set a PDUFA date of May 8, 2027, and the company is prepared for launch upon approval. Encaleret has shown positive Phase 3 results, with potential to transform ca…

BioMarin: Commercial Muscle Behind the Next Rerating

BioMarin: Commercial Muscle Behind the Next Rerating

BioMarin's nine commercial therapies and strong free cash flow create a safety net that the market underappreciates. With positive VOXZOGO Phase 3 data and a clear path to an sNDA submission in Q3 2026, paired with a conservative balance sheet (about $2.8B cash) and $767M in free cash flow, BMRN looks positioned for a mid-term upside. This trade ta…

Ontario Wildfires Swell as Smoke Continues to Affect U.S. Midwest Air Quality

Ontario Wildfires Swell as Smoke Continues to Affect U.S. Midwest Air Quality

Ontario officials report the area affected by wildfires has expanded to 735,000 hectares, with 190 active fires and about 1,800 residents evacuated from remote northwestern communities. While air quality has improved across much of southern Ontario and parts of the U.S. Northeast, smoke continues to produce unhealthy conditions across sections of t…

Ukraine to Send Drones to U.S. for Pentagon's Drone Dominance Program

Ukraine to Send Drones to U.S. for Pentagon's Drone Dominance Program

Ukraine has agreed to export drones to the United States to take part in the U.S. Department of Defense's Drone Dominance competition. Six Ukrainian companies have permission to supply roughly 100 drones each, as Kyiv and Washington continue discussions on a larger drone transfer framework. The move occurs amid growing international interest in Ukr…

Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change

Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change

Trinity Biotech plc plans to change its ADS ratio from one ADS representing 20 Class A ordinary shares to one ADS representing 600 Class A ordinary shares. This reverse ADS split aims to regain compliance with Nasdaq's $1.00 minimum bid price requirement and broaden the investor base by increasing the ADS price. The change will take effect on July …

Southern Europe Faces Escalating Wildfire Threat as Heatwave Persists

Southern Europe Faces Escalating Wildfire Threat as Heatwave Persists

Widespread heat and dry conditions have driven a surge in wildfires across Spain and France, with authorities warning the risk of new blazes remains very high. Spain's largest fire this year in Guadalajara has begun to stabilise, allowing some residents to return, while France contends with multiple outbreaks, fatalities among firefighters and cont…

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

Radiopharm Theranostics announced encouraging Phase 1 clinical trial results for RAD204, a PD-L1-targeted radiotherapeutic in development for advanced solid tumors post-immunotherapy. The first two patients at the highest dose showed durable partial tumor responses and remain progression-free, with RAD204 exhibiting a favorable safety profile and n…

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

Royalty Pharma has secured a significant royalty interest in AstraZeneca's cliramitug, a promising Phase 3 therapy targeting transthyretin amyloidosis with cardiomyopathy (ATTR-CM), by acquiring part of Neurimmune’s royalty rights for up to $425 million. Cliramitug represents a first-in-class approach aimed at removing amyloid deposits rather than …

uniQure to Announce Second Quarter 2026 Financial Results

uniQure to Announce Second Quarter 2026 Financial Results

uniQure N.V., a gene therapy company specializing in transformative treatments, announced it will release its second quarter 2026 financial results before market open on July 29, 2026, followed by a management conference call. The company highlighted its approval for gene therapy in hemophilia B and ongoing development for other severe diseases.

Buy the Relief Rally: Western Alliance Q2 Could Quiet Credit Anxiety

Buy the Relief Rally: Western Alliance Q2 Could Quiet Credit Anxiety

Western Alliance (WAL) looks positioned to see a near-term relief rally if Q2 results provide clarity on recent loan losses and CRE exposure. The bank trades at ~9x earnings and 1.15x book with a $8.8B market cap. This trade idea is a tactical long: enter near $79.00, stop at $72.00, target $92.00 over a 180-trading-day horizon, with clear risk man…

Oatly Reports Second Quarter 2026 Financial Results

Oatly Reports Second Quarter 2026 Financial Results

Oatly Group AB reported second quarter 2026 financial results with revenue of $240.1 million, a 15.2% increase year-over-year, driven by strong growth in Europe, North America, and Greater China. The company improved gross margin to 33.9% and narrowed net loss to $31.3 million from $55.9 million a year ago. Adjusted EBITDA improved to a slight posi…

Stifel Reports Second Quarter 2026 Results

Stifel Reports Second Quarter 2026 Results

Stifel Financial Corp. reported net revenues of $1.45 billion and net income of $217.2 million for Q2 2026, marking the best second quarter in company history. Significant growth was driven by increased investment banking revenues, asset management, and commission revenues. The company also achieved record client assets, improved operating leverage…

Advantage Solutions to Report Second Quarter 2026 Financial Results

Advantage Solutions to Report Second Quarter 2026 Financial Results

Advantage Solutions Inc., a leading omnichannel retail solutions agency, will report its second quarter 2026 financial results on August 5, 2026, followed by a conference call and webcast for investors and interested parties. The company provides data and technology-powered services to consumer-packaged goods brands and retailers to drive demand an…

Rogers Communications Reports Second Quarter 2026 Results

Rogers Communications Reports Second Quarter 2026 Results

Rogers Communications released its Q2 2026 results showing strong growth in total service revenue (+8%) and adjusted EBITDA (+3%), with stable wireless revenue and growth in cable and media segments. The company completed an agreement to acquire the remaining 25% stake in Maple Leaf Sports & Entertainment, positioning it for further sports monetiza…